SEC Form 4 · accession 0001209191-15-063821
PUMA BIOTECHNOLOGY, INC. · PBYI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Richard Paul Bryce
Officer — SR VP, CLINICAL RESEARCH & DEV
Period of report
Aug 3, 2015
Accepted (ET)
Aug 4, 2015 · 7:35 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001401667
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| STOCK OPTION (RIGHT TO BUY)F1 | $87.88 | Aug 3, 2015 | A | 31,500 | A | — | Aug 3, 2025 | COMMON STOCK | 31,500 | 31,500 | D |
Explanation of responses
- F1The vesting commencement date ("Vesting Commencement Date") of the option is June 20, 2015. The option vests (i) with respect to one-third (1/3) of the shares underlying the option on the first anniversary of the Vesting Commencement Date and (ii) with respect to 1/36th of the shares underlying the option, on each monthly anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person's continued services with the Issuer.